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Abbreviations
DEN  Diethylnitrosamine
IHC  Immunehistochemistry
IL-6  Interleukine-6
mAb  Monoclonal antibody
NK cell  Natural killer cell
s.c.  Subcutaneous
TNF-α  Tumor necrosis factor alpha
Physical exercise has documented impact on health and 
well-being of humans, and is associated with a reduced 
risk of mortality [1]. Exercise has also been shown to 
have a preventive effect on the risk of cancer, i.e., leisure-
time exercise is associated with a lower cancer incidence. 
Although epidemiological studies of exercise and its impact 
on slowly developing diseases are often self-reported and 
might be biased by other lifestyle factors and often, avail-
able data strongly suggest exercise to be preventive for can-
cer [2, 3]. Concerning a potential role for exercise in cancer 
prognosis and therapy, physical activity has been reported 
to be associated with a lowered risk of disease recurrence 
(breast cancer and colorectal cancer) [3, 4]. However, data 
are needed in other cancers, and not much is known in 
terms of the optimal timing and type of activity. Moreover, 
the mechanism by which exercise impact on cancer risk 
and prognosis is largely unknown.
We recently took advantage of several murine tumor 
models to study the impact of exercise on cancer, and could 
demonstrate that voluntary exercise (wheel running) leads 
to a significant reduction in tumor size or incidence across 
the applied models [5]. Thus, exercise had a significant 
impact on tumor size in the transplanted lewis lung can-
cer and B16 melanoma models—the latter studied both 
as subcutaneous (s.c.) tumors, as well as lung metastases 
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established upon intravenous administration of cancer cells. 
Moreover, we could show an impact of exercise on tumor 
size and incidence on liver cancer using a diethylnitrosa-
mine (DEN) induced liver cancer model, as well as the 
spontaneous melanoma model GrM1. To gain insight into 
the mechanism, we used the transplanted B16 melanoma 
model and compared tumors from exercise and control 
animals and, by microarray, showed that pathways associ-
ated with immune function were significantly up-regulated 
in tumors from exercise animals. Using real-time PCR, 
we validated the elevated expression levels of selected 
transcripts, and took advantage of immunohistochemistry 
(IHC) and flow cytometry, to substantiate these findings at 
the cellular level. Thus, tumors from exercise animals had 
a much denser infiltration of immune cells; T cells, B cells, 
dendritic cells, and NK cells. Since in particular NK cells 
were repeatedly increased in both subcutaneous and lung 
metastases of B16 tumors, we first used nude mice to see if 
exercise would still have an impact in the absence of T and 
B cells. Indeed, this was the case. As a next step, we went 
back to using B16 melanoma in wild type C57BL/6 mice, 
and used anti-asialo monoclonal antibody to clear NK cells 
from the animals. Strikingly, this completely abolished the 
effect of exercise, demonstrating that at least in the used 
transplanted tumor model, NK cells were necessary and 
sufficient for the effect [5]. NK cells are known to be capa-
ble of killing cancer cells [6], but a link between NK cells 
and the exercise associated anti-tumor response had not 
previously been scrutinized.
Exercise in humans is associated with a range of physi-
ological changes, the magnitude of which is influenced by 
the intensity and duration of the exercise. Thus, there is an 
increase in cardiac output to meet oxygen demands, and a 
dramatic change in the pattern of blood flow. The metabolic 
rate goes up, and glucose consumption as well as output 
is increased, as is lactate levels due to anaerobic metabo-
lism in muscle cells. Moreover, the endocrine system plays 
a key role in integrating the physiological responses both 
during rest and exercise [7]. To this end, catecholamines 
including epinephrine (adrenaline), and norepinephrine 
(noradrenaline) are significantly elevated during exercise 
through increased release from the adrenal glands. These 
hormones are part of the fight-or-flight response associated 
with increases in heart rate, blood pressure, blood glucose 
levels—and; immune function. To the latter, although there 
are conflicting data on the subject, there is consensus that 
acute exercise leads to a rapid increase in blood counts of 
various immune cells [7], followed by a drop to below base-
line in turn followed by normalization of cell counts [8]. 
The most sensitive immune cell type to acute exercise is the 
NK cell [9], which are mobilized within minutes of exer-
cise [10]. Maximal mobilization of NK cells is achieved 
after 30  min of exercise, and prolonged training does not 
lead to increased NK cell levels, but max level of NK cells 
can be maintained up to 3 h by continued training [9]. NK 
cells were initially characterized by being able to kill target 
cells without prior priming [6], and they normally function 
to clear virus infected, stressed, or transduced cells. This 
exercise-induced mobilization of NK cells is supposedly 
installed mainly by an increase in catecholamines. To this 
point, among leucocytes, NK cells express the highest lev-
els of β-adrenergic receptors which is the receptor for cat-
echolamines, especially norepinephrine and epinephrine 
[11], and the exercise associated mobilization of NK cells 
can be mimicked by administration of epinephrine [12].
In part based on the above, we first looked at serum 
levels of epinephrine and norepinephrine in exercise and 
control animals, and found that exercise animals had sig-
nificantly higher amounts of both catecholamines. Moreo-
ver, we could block the effect of exercise on the increase 
in NK cell mobilization, immune cell influx to tumors, as 
well as impact on tumor progression by administration of 
the β-blocker propranolol [5]. Aiming at scrutinizing if epi-
nephrine was alone responsible, we administered epineph-
rine to the animals, which did, indeed, impact on NK fre-
quencies, immune cell infiltration into tumors, and size of 
tumors—but not as pronounced an effect as exercise. Thus, 
epinephrine is a key molecule in the exercise associated 
improved tumor control by cells of the immune system.
Since administration of epinephrine only partially mim-
icked exercise, we considered other molecules that could 
potentially play a role.
Exercise is associated with the release of myokines from 
the contracting muscles. One of the key myokines is inter-
leukine-6 (IL-6) which is also known from its wide rang-
ing and sometimes contrasting effects within the immune 
system. IL-6 is described to be pro-inflammatory in set-
tings of bacterial infections and chronic inflammation, 
yet act anti-inflammatory by inhibiting TNF-α and IL-1, 
and activation of immune suppressive IL-10 [13]. Dur-
ing exercise, the plasma level of IL-6 increases rapidly in 
an intensity-dependent manner, through the release from 
exercise-engaged muscles [14]. As NK cells express the 
IL-6 receptor complex, we speculated whether exercise-
mediated IL-6 release could play a role in, i.e., add to the 
effect of administration of epinephrine. We first cleared 
IL-6 using an IL-6 specific monoclonal antibody (mAb) 
which led to a diminished tumor control and also a less 
pronounced immune cell infiltration to the tumor; how-
ever, we could not mimic the role of IL-6 by administra-
tion of recombinant cytokine. Certainly, there could be 
many reasons for this: dosing, route of administration, tim-
ing related to levels of epinephrine, etc. At least one role 
IL-6 could play would be to increase mobilization of NK 
cells, since NK cells leaving the thymus were selectively 
expressing the IL-6α receptor. Cancer cells—including 
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melanomas—quite often express high levels of IL-6, which 
could, in turn, play a role in homing of NK cells expressing 
the IL-6 receptor. However, this is purely speculative and 
more work is needed to clarify the role of IL-6 in NK cell 
homing to the tumor site.
The data summarized above could have several impor-
tant implications in humans both in relation to cancer inci-
dence and therapy.
First, human NK cells express β-adrenergic recep-
tors and as already mentioned administration of epineph-
rine leads to mobilization of NK cells. Similarly, bouts 
of acute exercise lead to mobilization of leucocytes most 
pronouncedly NK cells, and thus, increase in systemic NK 
cell frequencies is a key immunological feature of exer-
cise in man as well as mouse [15]. It should be mentioned, 
however, that in all sc. B16 tumors from exercise mice, we 
also saw increased numbers of T cells. T cells also express 
β-adrenergic receptors and are thus also mobilized by epi-
nephrine. Moreover, killing of cancer cells by NK cells 
may have led to uptake of tumor antigen by dendritic cells, 
and induction of tumor-specific T-cell responses. In terms 
of the function of NK cells, although different in terms of 
cell surface markers and signalling molecules [16], there 
are basic similarities in terms of being similarly capable 
of recognizing and killing of cancer cells as a functional 
response to recognizing “missing self” [6]. NK cells may 
also recognize cancer cells by activating receptors, e.g., 
NKG2D recognizing ligands expressed on cancer cells 
[17]. Thus, exercise in humans mobilizes NK cells, and 
human NK cells are efficient cancer cell killers—and, 
therefore, could play a protective or therapeutic role in can-
cer. To this end, Moore and colleagues recently pooled data 
from 12 prospective cohorts with self-reported physical 
activity for association with incidence of 26 types of can-
cer, and could demonstrate that leisure-time physical activ-
ity is significantly associated with a lower risk of cancer, 
e.g., cancers of the oesophagus, liver, lung, kidney, colon, 
breast, and as well as leukemia and myeloma [2]. Strik-
ingly, two cancers showed physical activity associated with 
higher risk of cancer, melanoma, and prostate cancer. For 
melanoma, this could supposedly be due to sun exposure 
during exercise. For advanced prostate cancer, there was 
no relationship between physical activity and cancer, sug-
gesting that men that exercise, are more prone to be exam-
ined and diagnosed—in some cases with indolent prostate 
cancer. Nonetheless, with two exceptions, physical activity 
is associated with lower risks of a range of cancer types. 
Obviously, these data do not by itself reveal insight into the 
molecular or cellular background but underscore that the 
exercise associated immune mobilization could potentially 
play a role in cancer prevention. To this end, a key fea-
ture of the protective role of exercise in our mouse studies 
was an increased number of immune cells in tumors from 
exercise animals [5], a feature known to be associated with 
longer survival in humans [18]. Moreover, immune infil-
tration can be studied in humans by serial biopsies before 
and after exercise. Thorough studies of the composition of 
immune cells infiltrating the tumor could possibly reveal 
data to support the notion of improved immunological con-
trol of tumor progression, and set the stage for combination 
treatment as given in more detail below.
Second, in our fast growing transplantable  B16 mela-
noma model, NK cells were responsible for the anti-can-
cer effect of exercise, and NK cells had significant effect 
in the absence of T and B cells. As a consequence, it is 
possible that fast growing transplantable models in which 
NK cells do not play a substantial role would see limited 
or no effect of exercise. In our B16 model, the most pro-
nounced effect was achieved when exercise was initiated 
prior to inoculation of cancer cells. We also did studies in 
which exercise was initiated concurrent with cancer cell 
inoculation and saw only a trend towards smaller tumors 
in the exercise group [5]. Hence, it makes sense to specu-
late that prior exercise implies that more NK cells are in 
circulation and ready to home to the inoculation site and 
kill cancer cells immediately at the site of injection. Thus, 
we have no evidence that NK cells alone are responsible 
for the effect using more clinically relevant tumor models. 
In more slowly developing tumor models, e.g., the DEN or 
the GrM1 model, we are currently following the hypoth-
esis that NK cells are key cells in delivering the “spark” 
that could be a main denominator for setting the stage for 
induction of a full scale response involving all appropri-
ate cell types necessary for an anti-cancer immune attack: 
most importantly dendritic cells and T cells. This would be 
in line with the data suggesting NK cells to play a main 
role in very early phases of tumorigenesis and a less pro-
nounced role once the tumor is established [18, 19]. This 
notion is supported by the fact that solid tumors comprise 
quite few NK cells, whereas infiltrates of T cells are often 
present in more substantial numbers [20]. A key role of 
NK cells in protection rather than therapy is also suggested 
from a study in which NK cell levels were studied longitu-
dinally with an 11 year interval using a functional cytotox-
icity readout, which showed that a high level of cytotoxic 
activity among peripheral blood lymphocytes was associ-
ated with a lower risk of cancer [21]. Again, this suggests 
NK cells as active in early tumor surveillance.
In terms of translation to a human setting, maybe, the 
most important finding of our recent study is the impact on 
exercise shown using the chemically induced model (DEN) 
or the spontaneous melanoma model. In the DEN model, 
we saw a decreased in tumor incidence going from 70 to 
30%, and given the fact that the immune infiltrate in B16 
showed a significant increase not only in NK cells, but also 
dendritic cells, B cells, and T cells, we hypothesize that 
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in the slow growing more clinically relevant models, NK 
cells may be involved with early surveillance, while other 
immune subsets play a more important role in anti-tumor 
responses against the established tumor.
Third, given the immune cell mobilizing and tumor infil-
trating effect of exercise, this could potentially play a role 
as combination or conditioning partner to immune therapy. 
To this end, the immune check point inhibitory mAb are 
now approved in several cancers and the list of cancer indi-
cations is certain to increase. In particular, blockade of the 
PD-1 axis by mAbs seems to induce clinical responses by 
unleash of spontaneous tumor-specific immune responses 
at the tumor site [22]. Importantly, data are accumulating to 
suggest that patients whose tumors are characterized by a 
brisk infiltration of immune cells are more prone to respond 
to treatment [23]. As consequence, huge research efforts 
are undertaken to scrutinize methods by which tumors with 
limited or absent immune cell infiltrates, i.e., “cold tumors” 
can be turned into “hot” tumors with a brisk infiltration of 
anti-tumor immune cells, T cells, NK cells, dendritic cells, 
etc. Therefore, exercise prior to PD-1 therapy could rep-
resent a tool that condition patients to immunotherapy by 
increasing the immune infiltrate in the tumor, and in turn 
increase the chance for clinical response. Adoptive cell 
transfer (ACT) using tumor infiltrating lymphocytes (TIL) 
represents another breakthrough in immunotherapy of 
cancer. A very obvious requirement for clinical success is 
the presence of tumor-specific T cells in the tumors, since 
these cells prepare the platform for expansion in vitro and 
administration of high numbers of tumor-specific T cells 
back to the patient. In melanoma patients, 50% of patients 
respond to treatment with an impressive 20% experiencing 
lasting complete, i.e., supposedly curative responses [24, 
25]. As mentioned, exercise prior to surgery for harvest 
of T cells could possibly promote the quantity of cells and 
maybe also the quality of “new” immune cells in tumor. 
Prior to clinical testing, this could be studied by harvest-
ing of serial biopsies for studies of immune cell infiltration 
and in vitro functionality of immune cells, in the pre-clini-
cal and clinical setting, by studying needle biopsies before 
and after monitored exercise programs. Several lines of 
evidence point at the immune system as being crucial also 
for the efficacy of chemotherapy [26]. If substantiated by 
human studies, exercise could play a role by improving also 
response to the conventional treatments [27].
Cancer immunotherapy is now clinically validated in 
many cancers, and even in very late stage patients, last-
ing complete responses are not uncommon. However, for 
most treatments, the majority of patients do not respond 
and predictive markers are missing. Hence, there is an 
urgent call for characterization of predictive markers and 
tools to increase response to therapy. To the latter, exer-
cise is known to be healthy in an array of aspects in the 
life of modern human beings. Based on our data in mouse 
models, we suggest that exercise could represent a suit-
able combination partner to immune therapy in cancer 
patients, facilitating improved response rates and more 
frequent complete lasting responses. Moreover, exer-
cise may directly—as a key component of a healthy life-
style—delay or prevent tumor development.
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